World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   49 records for 15 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2
Recruitment statusProspective RegistrationMain ID Public TitleDate of RegistrationResults available
AuthorisedYesEUCTR2016-004019-11-IT
A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety and pharmakokinetics of HD201 to Herceptin┬« in patients with HER2+ early breast cancer 09/04/2018 
RecruitingNoCTRI/2017/09/009894
Heat therapy(agnikarma) in Tennis Elbow
22-09-2017 
Not recruitingYesNCT03258723
Diabetes Prevention With Lifestyle Intervention and Metformin Escalation
20/08/2017 
AuthorisedYesEUCTR2015-003332-13-SK
A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT)
Recruitment statusMain IDPublic titleDate of registrationResults available
AuthorisedEUCTR2015-003332-13-NO A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 21/04/2016 
AuthorisedEUCTR2015-003332-13-GR A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 24/05/2016 
AuthorisedEUCTR2015-003332-13-ES A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 19/01/2016 
AuthorisedEUCTR2015-003332-13-PT A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 08/04/2016 
AuthorisedEUCTR2015-003332-13-HR A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 06/07/2016 
Not RecruitingEUCTR2015-003332-13-DK A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 07/04/2016 
AuthorisedEUCTR2015-003332-13-LV A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 12/04/2016 
AuthorisedEUCTR2015-003332-13-HU A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 05/05/2016 
AuthorisedEUCTR2015-003332-13-LT A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 29/04/2016 
AuthorisedEUCTR2015-003332-13-BE A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 07/04/2016 
AuthorisedEUCTR2015-003332-13-GB A Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 11/04/2016 
AuthorisedEUCTR2015-003332-13-CZ A Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 06/04/2016 
AuthorisedEUCTR2015-003332-13-IE A Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 08/04/2016 
AuthorisedEUCTR2015-003332-13-AT A Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 01/06/2016 
AuthorisedEUCTR2015-003332-13-FI A Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 19/04/2016 
AuthorisedEUCTR2015-003332-13-BG A Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 25/03/2016 
AuthorisedEUCTR2015-003332-13-PL A Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 12/04/2016Yes
Not RecruitingEUCTR2015-003332-13-IT A Study Comparing ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response to csDMARDs Alone (SELECT-NEXT) 28/02/2018 
04/11/2015 
RecruitingYesNCT02313805
The Effect of a Checklist on the Quality of Education During Insulin Initiation by Trained Medical Students
08/12/2014 
Not recruitingNoNCT02321150
A Novel Technique for the Removal of Pterygiums
03/12/2014 
RecruitingYesNCT02266303
The Effect of a Checklist on the Education of Simulated Patients During Insulin Initiation
10/10/2014 
Not recruitingNoNCT02059122
Sensitivity Study of Diagnostic for Early Detection of Dengue Infection
07/02/2014 
Not recruitingYesNCT02019264
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors 18/12/2013 
RecruitingYesNCT02019420
Tedizolid Phosphate (TR-701 FA) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)
Recruitment statusMain IDPublic titleDate of registrationResults available
AuthorisedEUCTR2013-004154-22-ES The purpose of this study is to learn if an experimental antibiotic called TR-701 FA can safely and effectively treat ventilated patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia. The experimental antibiotic will be tested against the already approved antibiotic Linezolid. The sponsor of the study wants to prove, that the new medication isn't inferior regarding efficacy and safety as compared to the already approved medication Linezolid. 19/03/2014 
AuthorisedEUCTR2013-004154-22-LV The purpose of this study is to learn if an experimental antibiotic called TR-701 FA can safely and effectively treat ventilated patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia. The experimental antibiotic will be tested against the already approved antibiotic Linezolid. The sponsor of the study wants to prove, that the new medication isn't inferior regarding efficacy and safety as compared to the already approved medication Linezolid. 02/01/2014 
AuthorisedEUCTR2013-004154-22-GR The purpose of this study is to learn if an experimental antibiotic called TR-701 FA can safely and effectively treat ventilated patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia. The experimental antibiotic will be tested against the already approved antibiotic Linezolid. The sponsor of the study wants to prove, that the new medication isn't inferior regarding efficacy and safety as compared to the already approved medication Linezolid. 21/03/2014 
AuthorisedEUCTR2013-004154-22-HR The purpose of this study is to learn if an experimental antibiotic called TR-701 FA can safely and effectively treat ventilated patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia. The experimental antibiotic will be tested against the already approved antibiotic Linezolid. The sponsor of the study wants to prove, that the new medication isn't inferior regarding efficacy and safety as compared to the already approved medication Linezolid. 02/12/2014 
AuthorisedEUCTR2013-004154-22-GB The purpose of this study is to learn if an experimental antibiotic called TR-701 FA can safely and effectively treat ventilated patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia. The experimental antibiotic will be tested against the already approved antibiotic Linezolid. The Sponsor of the study wants to prove that the new medication is not inferior regarding efficacy and safety as compared to the already approved medication Linezolid 19/05/2014 
AuthorisedEUCTR2013-004154-22-HU The purpose of this study is to learn if an experimental antibiotic called TR-701 FA can safely and effectively treat ventilated patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia. The experimental antibiotic will be tested against the already approved antibiotic Linezolid. The sponsor of the study wants to prove, that the new medication isn't inferior regarding efficacy and safety as compared to the already approved medication Linezolid. 04/02/2014 
AuthorisedEUCTR2013-004154-22-BE The purpose of this study is to learn if an experimental antibiotic called TR-701 FA can safely and effectively treat ventilated patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia. The experimental antibiotic will be tested against the already approved antibiotic Linezolid. The sponsor of the study wants to prove, that the new medication isn't inferior regarding efficacy and safety as compared to the already approved medication Linezolid. 06/03/2014 
AuthorisedEUCTR2013-004154-22-SK The purpose of this study is to learn if an experimental antibiotic called TR-701 FA can safely and effectively treat ventilated patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia. The experimental antibiotic will be tested against the already approved antibiotic Linezolid. The sponsor of the study wants to prove, that the new medication isn't inferior regarding efficacy and safety as compared to the already approved medication Linezolid. 01/04/2014 
AuthorisedEUCTR2013-004154-22-PT A comparison of tedizolid and linezolid in hospital or ventilator acquired pneumonia. 21/07/2016 
AuthorisedEUCTR2013-004154-22-CZ The purpose of this study is to learn if an experimental antibiotic called TR-701 FA can safely and effectively treat ventilated patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia. The experimental antibiotic will be tested against the already approved antibiotic Linezolid. The sponsor of the study wants to prove, that the new medication isn't inferior regarding efficacy and safety as compared to the already approved medication Linezolid. 03/04/2014 
Not RecruitingEUCTR2013-004154-22-AT The purpose of this study is to learn if an experimental antibiotic called TR-701 FA can safely and effectively treat ventilated patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia. The experimental antibiotic will be tested against the already approved antibiotic Linezolid. The sponsor of the study wants to prove, that the new medication isn't inferior regarding efficacy and safety as compared to the already approved medication Linezolid. 04/02/2014 
AuthorisedEUCTR2013-004154-22-EE The purpose of this study is to learn if an experimental antibiotic called TR-701 FA can safely and effectively treat ventilated patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia. The experimental antibiotic will be tested against the already approved antibiotic Linezolid. The sponsor of the study wants to prove, that the new medication isn't inferior regarding efficacy and safety as compared to the already approved medication Linezolid. 18/05/2014 
AuthorisedEUCTR2013-004154-22-DE The purpose of this study is to learn if an experimental antibiotic called TR-701 FA can safely and effectively treat ventilated patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia. The experimental antibiotic will be tested against the already approved antibiotic Linezolid. The sponsor of the study wants to prove, that the new medication isn't inferior regarding efficacy and safety as compared to the already approved medication Linezolid. 25/02/2014 
Not RecruitingEUCTR2013-004154-22-IT The purpose of this study is to learn if an experimental antibiotic called TR- 701 FA can safely and effectively treat ventilated patients with hospitalacquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia. The experimental antibiotic will be tested against the already approved antibiotic Linezolid. The sponsor of the study wants to prove, that the new medication isn't inferior regarding efficacy and safety as compared to the already approved medication Linezolid. 27/02/2018Yes
18/12/2013 
      
1 2
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history